147 related articles for article (PubMed ID: 31428683)
1. PYCR1 is Associated with Papillary Renal Cell Carcinoma Progression.
Wang QL; Liu L
Open Med (Wars); 2019; 14():586-592. PubMed ID: 31428683
[TBL] [Abstract][Full Text] [Related]
2. Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma.
Ye Y; Wu Y; Wang J
Cancer Manag Res; 2018; 10():6399-6407. PubMed ID: 30568501
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma.
Cui XF; Cui XG; Leng N
J Toxicol Pathol; 2019 Oct; 32(4):245-251. PubMed ID: 31719751
[TBL] [Abstract][Full Text] [Related]
4. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
5. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.
Zhuang J; Song Y; Ye Y; He S; Ma X; Zhang M; Ni J; Wang J; Xia W
J Transl Med; 2019 Oct; 17(1):343. PubMed ID: 31619254
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.
Xu Y; Zuo W; Wang X; Zhang Q; Gan X; Tan N; Jia W; Liu J; Li Z; Zhou B; Zhao D; Xie Z; Tan Y; Zheng S; Liu C; Li H; Chen Z; Yang X; Huang Z
Int J Biol Sci; 2021; 17(9):2223-2239. PubMed ID: 34239351
[TBL] [Abstract][Full Text] [Related]
7. Pro-tumorigenic activity of PYCR1 in gastric cancer through regulating the PI3K/AKT signaling.
Xiao H; Huang J; Wu H; Li Y; Wang Y
Heliyon; 2024 Mar; 10(5):e26883. PubMed ID: 38455525
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.
Guo J; Cheng X; Tian Y; Li B; Zhang X; Gao X; An Y
Reprod Biol; 2021 Sep; 21(3):100534. PubMed ID: 34271243
[TBL] [Abstract][Full Text] [Related]
9. PYCR1 expresses in cancer-associated fibroblasts and accelerates the progression of C6 glioblastoma.
Zhang M; Bi B; Liu G; Fan X
Histol Histopathol; 2024 May; ():18762. PubMed ID: 38826151
[TBL] [Abstract][Full Text] [Related]
10. Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome.
Xiao S; Li S; Yuan Z; Zhou L
Ann Transl Med; 2020 Aug; 8(15):937. PubMed ID: 32953737
[TBL] [Abstract][Full Text] [Related]
11. PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling.
Du S; Sui Y; Ren W; Zhou J; Du C
J Bioenerg Biomembr; 2021 Apr; 53(2):247-258. PubMed ID: 33689096
[TBL] [Abstract][Full Text] [Related]
12. Pyrroline-5-Carboxylate Reductase 1 Accelerates the Migration and Invasion of Nonsmall Cell Lung Cancer
Sang S; Zhang C; Shan J
Cancer Biother Radiopharm; 2019 Aug; 34(6):380-387. PubMed ID: 30916574
[No Abstract] [Full Text] [Related]
13. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
[TBL] [Abstract][Full Text] [Related]
14. Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.
Cai F; Miao Y; Liu C; Wu T; Shen S; Su X; Shi Y
Oncol Lett; 2018 Jan; 15(1):731-740. PubMed ID: 29403556
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1).
Li Z; Zhou X; Huang J; Xu Z; Xing C; Yang J; Zhou X
Bioengineered; 2021 Dec; 12(2):9766-9778. PubMed ID: 34696668
[TBL] [Abstract][Full Text] [Related]
16. PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize.
Zhang L; Zhao X; Wang E; Yang Y; Hu L; Xu H; Zhang B
Transl Oncol; 2023 Jun; 32():101667. PubMed ID: 37018868
[TBL] [Abstract][Full Text] [Related]
17. RAC3 Promotes Proliferation, Migration and Invasion via PYCR1/JAK/STAT Signaling in Bladder Cancer.
Cheng C; Song D; Wu Y; Liu B
Front Mol Biosci; 2020; 7():218. PubMed ID: 33062641
[TBL] [Abstract][Full Text] [Related]
18. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.
Sun T; Song Y; Yu H; Luo X
Cancer Biol Ther; 2019; 20(6):760-773. PubMed ID: 30810442
[TBL] [Abstract][Full Text] [Related]
19. Increased PYCR1 mRNA predicts poor prognosis in kidney adenocarcinoma: A study based on TCGA database.
Zhang T; Liu Y; Liu W; Li Q; Hou W; Huang Y; Lv P; Meng L; Li Y; Jia Y; Liu X; Zuo Z
Medicine (Baltimore); 2021 Sep; 100(38):e27145. PubMed ID: 34559102
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer.
Zeng T; Zhu L; Liao M; Zhuo W; Yang S; Wu W; Wang D
Med Oncol; 2017 Feb; 34(2):27. PubMed ID: 28078560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
